CAMBRIDGE, Mass. — August 14, 2025 — Leads & Copy — CAMP4 Therapeutics Corporation (Nasdaq: CAMP) shared positive translational data from its SYNGAP1-related disorders program, showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The company also announced it is initiating GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025. Additionally, dosing has been completed in multiple ascending dose (MAD) cohort 3 of CMP-CPS-001, with data from single ascending dose (SAD) & MAD cohorts expected in Q4 2025.
Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4, stated the company presented compelling translational data from the SYNGAP1 program, reinforcing confidence in CMP-SYGNAP-01’s potential to transform the lives of patients living with the devastating neurological disorder.
In corporate highlights, CAMP4 presented new translational data from the SYNGAP1-related disorders program and highlighted interim safety results from the ongoing Phase 1 UCD trial at the 28th American Society of Gene and Cell Therapy Annual Meeting. Expects to initiate GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025; potential to initiate a global Phase 1/2 trial as early as H2 2026. Dosing was completed in the third MAD cohort in the ongoing Phase 1 clinical trial of CMP-CPS-001; and expect to report data from all four cohorts of the SAD portion and the first three cohorts of the MAD portion of the trial, including safety, pharmacokinetic and pharmacodynamic biomarker results, in Q4 2025.
The company’s cash, cash equivalents, and marketable securities as of June 30, 2025, were $39.1 million, compared to $49.3 million as of March 31, 2025.
Investor Relations: Dan Ferry (US), LifeSci Advisors, daniel@lifesciadvisors.com; Media: Jason Braco, Ph.D., LifeSci Communications, jbraco@lifescicomms.com
Source: CAMP4 Therapeutics Corporation
